# Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

> **NCT03024684** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Chiayi Christian Hospital** · enrollment: 240 (actual)

## Conditions studied

- HepatoCellular Carcinoma

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03024684
- **Lead sponsor:** Chiayi Christian Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-03
- **Primary completion:** 2025-01
- **Final completion:** 2027-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024684, "Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03024684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*